bimekizumab (Bimzelx) Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
bimekizumab (Bimzelx) For the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs)andadults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.
bimekizumab (Bimzelx) Alone or in combination with methotrexate (MTX), is anticipated to be indicated for the treatment of active psoriatic arthritis (PsA) in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).
bimekizumab (Bimzelx) For the treatment of active moderate to severe hidradenitis suppurativa (HS) in adults with an inadequate response to conventional systemic HS therapy.
December 2023 decisions news release The Scottish Medicines Consortium (SMC), which advises on newly-licensed medicines for use by NHSScotland, has today (Monday, December 11) published advice on seven medicines.
November 2023 decisions news release The Scottish Medicines Consortium (SMC), which advises on newly-licensed medicines for use by NHSScotland, has today (Monday, November 13) published advice on 9 medicines.
